PRIMARY PERITONEAL CARCINOMA AFTER PROPHYLACTIC OOPHORECTOMY IN WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER - A REPORT OF THE GILDA-RADNER-FAMILIAL-OVARIAN-CANCER-REGISTRY

被引:0
|
作者
PIVER, MS
JISHI, MF
TSUKADA, Y
NAVA, G
机构
[1] Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
关键词
FAMILIAL OVARIAN CANCER; PERITONEAL CARCINOMA; PROPHYLACTIC OOPHORECTOMY;
D O I
10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. According to previous reports, primary peritoneal carcinoma indistinguishable from primary ovarian adenocarcinoma had developed in five women with a history of familial ovarian cancer who had undergone prophylactic oophorectomy. Methods. The records from the Gilda Radner Familial Ovarian Cancer Registry were reviewed for instances of prophylactic oophorectomy and cases of primary peritoneal carcinoma occurring after prophylactic oophorectomy. Results. From 1981 through July 1992, the Gilda Radner Familial Ovarian Cancer Registry accessioned 931 families (a total of 2221 cases of familial ovarian cancer). Currently, 324 women in these families have undergone prophylactic oophorectomy as a preventive measure against the subsequent development of ovarian cancer. Primary peritoneal carcinoma indistinguishable histologically from primary ovarian adenocarcinoma has developed in six of these women 1-27 years after prophylactic oophorectomy. Conclusions. Based on this finding and other reports of such primary peritoneal carcinoma, a prospective international study is planned. This study will compare the incidence of peritoneal carcinoma in first- or second-degree relatives who underwent prophylactic oophorectomy because of a family history of ovarian cancer with that of those who did not undergo prophylactic oophorectomy.
引用
收藏
页码:2751 / 2755
页数:5
相关论文
共 50 条
  • [41] Evaluation of Peritoneal Cancer Index as a Prognostic Marker in Primary Advanced Epithelial Ovarian Carcinoma Undergoing "Interval Cytoreductive Surgery" After Neoadjuvant Chemotherapy
    Bansal, Babul
    Ray, Mukurdipi
    Barua, Areendam
    Saikia, Jyoutishman
    Deo, Suryanarayana
    JOURNAL OF GYNECOLOGIC SURGERY, 2021, 37 (04) : 331 - 336
  • [42] Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations"
    Olivier, RI
    van Beurden, M
    GYNECOLOGIC ONCOLOGY, 2005, 99 (02) : 520 - 521
  • [43] Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?
    David Pierce Mysona
    Sharad Ghamande
    Jin-Xiong She
    Lynn Tran
    Paul Tran
    Bunja J. Rungruang
    John K. Chan
    Victoria Bae-Jump
    Paola A. Gehrig
    Annals of Surgical Oncology, 2021, 28 : 3605 - 3615
  • [44] Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?
    Mysona, David Pierce
    Ghamande, Sharad
    She, Jin-Xiong
    Tran, Lynn
    Tran, Paul
    Rungruang, Bunja J.
    Chan, John K.
    Bae-Jump, Victoria
    Gehrig, Paola A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (07) : 3605 - 3615
  • [45] Improved surgical outcomes after neoadjuvant chemotherapy among women with advanced stage ovarian, fallopian tube, or primary peritoneal cancer with disease involving all four quadrants
    Benn, T.
    Kizer, N.
    Gao, F.
    Zighelboim, I.
    Thaker, P.
    Powell, M.
    Mutch, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S77 - S78
  • [46] BRCA1/2 mutation frequency and patterns of treatment response in Asian women with ovarian, primary peritoneal or fallopian tube carcinoma (OPFC): experience from an Asian cancer centre
    Heong, V. Y. M.
    Ong, P. Y.
    Wan, L. Yi
    Lim, S. E.
    Lee, S. C.
    Tan, D. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 81 - 81
  • [47] Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial.
    Garcia, AA
    Oza, AM
    Hirte, H
    Fleming, G
    Tsao-Wei, D
    Roman, L
    Swenson, S
    Gandara, D
    Scudder, S
    Morgan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 455S - 455S
  • [48] Survival after maximum effort cytoreductive surgery and platinum-based chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma and primary peritoneal carcinomatosis: Experience of a Public University Hospital in Spain
    Khosravi-Shahi, Parham
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    GACETA MEXICANA DE ONCOLOGIA, 2019, 18 (01): : 13 - 21
  • [49] A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens.
    Moore, Kathleen N.
    Rimel, Bj
    Agarwal, Shefali
    Balser, John
    Martell, Robert E.
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results
    Vergote, Ignace
    Hanker, Lars Christian
    Floquet, Anne
    Rau, Joern
    Kim, Jae-Weon
    Izquierdo, Eugenia Ortega
    Friedlander, Michael
    Pignata, Sandro
    Fujiwara, Keiichi
    Colombo, Nicoletta
    Mirza, Mansoor Raza
    Monk, Bradley J.
    Moertl, Manfred
    Calvert, Paula
    Herzog, Thomas J.
    Jackisch, Christian
    Meunier, Jerome
    Lee, Jung-Yun
    Belau, Antje Kristina
    Du Bois, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)